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ABSTRACT Macaques play a central role in the development of human tuberculosis
(TB) vaccines. Immune and challenge responses differ across macaque and human
subpopulations. We used novel immunostimulation/immunodynamic modeling methods
in a proof-of-concept study to determine which macaque subpopulations best predicted
immune responses in different human subpopulations. Data on gamma interferon (IFN-
)-secreting CD4 T cells over time after recent Mycobacterium bovis BCG vaccination
were available for 55 humans and 81 macaques. Human population covariates were
baseline BCG vaccination status, time since BCG vaccination, gender, and the monocyte/
lymphocyte cell count ratio. The macaque population covariate was the colony of origin.
A two-compartment mathematical model describing the dynamics of the IFN- T cell re-
sponse after BCG vaccination was calibrated to these data using nonlinear mixed-effects
methods. The model was calibrated to macaque and human data separately. The associ-
ation between subpopulations and the BCG immune response in each species was
assessed. The macaque subpopulations that best predicted immune responses in
different human subpopulations were identiﬁed using Bayesian information crite-
ria. We found that the macaque colony and the human baseline BCG status were
signiﬁcantly (P  0.05) associated with the BCG-induced immune response. For
humans who were BCG naïve at baseline, Indonesian cynomolgus macaques and
Indian rhesus macaques best predicted the immune response. For humans who
had already been BCG vaccinated at baseline, Mauritian cynomolgus macaques
best predicted the immune response. This work suggests that the immune re-
sponses of different human populations may be best modeled by different ma-
caque colonies, and it demonstrates the potential utility of immunostimulation/
immunodynamic modeling to accelerate TB vaccine development.
KEYWORDS nonhuman primates, T-cell immunity, bacillus Calmette-Guérin,
interferons, mathematical modeling, tuberculosis, tuberculosis vaccines
Tuberculosis (TB) disease remains a major global health problem (1), and Mycobac-terium tuberculosis bacillus Calmette-Guérin (BCG), the only licensed TB vaccine,
exhibits variable efﬁcacy (2, 3). In order to reach WHO TB control goals, a new, effective
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vaccine is vital (4). Animal models are used in almost every aspect of vaccine devel-
opment, including helping to understand the transmission dynamics of the disease and
the immunogenicity and efﬁcacy of vaccines (5). They are therefore a vital and efﬁcient
tool in vaccine development (6). In preclinical TB vaccine research, nonhuman primates
(NHPs) are a valuable animal model (7, 8) and are genetically and physiologically more
similar to humans than small animals with respect to TB disease and immune response
(7, 9).
Historically, rhesus (Macaca mulatta) (10) and cynomolgus (Macaca fascicularis) (11)
macaque species have been used as the primary NHP models in TB vaccine research
(12–14). Both species have been shown to respond to BCG vaccination, which affords
them partial protection from TB (15–19); however, it has been shown that the same
experimental conditions (infection with Mycobacterium tuberculosis following vaccina-
tion or a vaccine immune response) may lead to divergent outcomes for the two
species (7, 20–22). Furthermore, the colony (country of origin) of macaque, even within
the same species, has been shown to affect the level of protection against infection and
the level of response after vaccination. For example, differing levels of protection have
been observed for Chinese and Mauritian cynomolgus macaques: Mauritian cynomol-
gus macaques developed end-stage progressive TB in 7 weeks, while Chinese cyno-
molgus macaques remained healthy past the end of the study (12 weeks) (23).
These differences suggest that the immune responses of different human popula-
tions (e.g., those with previous BCG vaccination or those who are BCG naïve) may be
best modeled by different macaque colonies. In 2014, the Bill and Melinda Gates
Foundation adopted a new strategy for the selection of new TB vaccine candidates for
clinical testing based on immune response and challenge results in NHPs (24). There-
fore, in order to increase the likelihood of developing an effective vaccine, it is critical
to identify and understand differences between macaque populations.
Here we focus on establishing the most representative NHP model for modeling the
gamma interferon (IFN-) immune responses of adult humans in the UK following
recent BCG vaccination, as one example of the prediction of vaccine immune responses
in humans from a macaque animal model.
For this purpose, we conduct a proof-of-concept study to evaluate the potential use
of novel immunostimulation/immunodynamic (IS/ID) modeling methods in vaccine
immune response translation between species. A mechanistic mathematically based
approach is used to quantify the dynamics of the immune response. By building the
mathematical models on the basis of quantitative immunological data, it is possible to
describe how these mechanisms may differ within and between species and to draw
quantitative comparisons. Such modeling techniques are commonly used in drug
development (pharmacokinetic/pharmacodynamic modeling) to translate drug re-
sponses between species (25–27) but have yet to be used in vaccine development.
First, we develop a model of IFN--producing CD4 T cell dynamics after BCG
vaccination and assess the suitability of the model structure for predicting responses by
calibrating the model to the data (analysis 1). We investigate the impact of the human
and macaque population covariates to explain the within-population variation in
responses, which our previous analysis on humans (28) showed can have a substantial
impact on the magnitude of the response (analysis 2). We then test which calibrated
macaque models best predict human IFN- responses (analysis 3). Finally, we use the
calibrated mathematical models for macaque and human subpopulations to predict
the dynamics of the constituent T cell populations over time (analysis 4).
RESULTS
Analysis 1. Calibration of the model to IFN- data and exploration of model
predictions for macaques and humans separately. Our mathematical model repre-
senting the immune response dynamics of two CD4 T cell populations secreting IFN-
is diagramed in Fig. 1. The estimated parameter values for both macaques and humans
can be found in Table 1. The visual predictive check (VPC) plots in Fig. 2 show that the
ranges for macaques and humans in the model simulation cover the empirical data,
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indicating that our model yields a good representation of the empirical data. Further
diagnostic plots and model prediction plots can be found in Fig. S3 to S7 in the
supplemental material.
Analysis 2. Population covariate impact on within-population variation in model
parameter estimates. We found two covariates to be important: stratifying macaques
by colony and humans by baseline BCG status reduced the within-population variation
in the initial transitional effector memory cell count (TEM0) for macaques, TEM0 for
humans, and the human gamma probability density function (PDF) multiplier and scale
parameters (parameters L and h) (Table 1; see also Tables S7 to S13 and Fig. S8 to S12
in the supplemental material). The VPC and further diagnostic plots for the subpopu-
lation models show that the model describes the data adequately (see Fig. S13 to S18
in the supplemental material). Accounting for the population covariates reduced the
Bayesian information criterion (BIC) value signiﬁcantly, by 73, for humans from that in
analysis 1 (BIC values, 2,779 in analysis 1 and 2,706 in analysis 2 [Table 1]) and decreased
it by 2 for macaques (BIC values, 7,253 in analysis 1 and 7,251 in analysis 2 [Table 1]).
The model-predicted total mean number of IFN--secreting cells (transitional effector
memory [TEM] cells plus central memory [CM] cells) over time is shown in Fig. 3 as a
visual assessment of the goodness of ﬁt of the model to the mean empirical data. Also,
Fig. S19 and S20 in the supplemental material show the 10th to 90th percentiles of
model predictions after accounting for within-population variation.
Analysis 3. Which macaque subpopulations best predicted immune responses
in different human subpopulations? The calibrated model for Indonesian cynomol-
gus macaques from analysis 2 provided the lowest BIC values for the human population
that was BCG naïve at baseline (BCG: N), and that for Indian rhesus macaques provided
the second lowest BIC value (1,357 and 1,391, respectively [Fig. 4; see also Fig. S20 to
S27 in the supplemental material]). The calibrated model for Mauritian cynomolgus
macaques best represented the human population that had already been BCG vacci-
nated prior to baseline (BCG: Y) (BIC value, 1,608 [Fig. 4; also Fig. S21 to S28]).
Analysis 4. Predicted numbers of TEM and resting CM cells over time. Figure 5
shows the model-predicted numbers of total (transitional effector memory and central
memory) cells secreting IFN-, over time, for the mean macaque and human subpop-
FIG 1 (A) Schematic of the mathematical model representing the immune response dynamics of two CD4 T cell populations secreting
IFN-. (B) Depiction of the changes in the recruitment rate of transitional effector memory cells () over time. (C) Key model parameters.
Equations may be found in the supplemental material.
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ulation data. These model dynamics present a prediction for the phenotypic behavior
of CD4 T cells and the ways in which they differ between species and subpopulations,
which can be validated experimentally.
DISCUSSION
In our proof-of-concept study, we applied novel immunostimulation/immunody-
namic (IS/ID) modeling to BCG immune response data and found that the macaque
colony and the human baseline BCG status were signiﬁcantly (P 0.05) associated with
the BCG-induced IFN- immune response. No other population covariates were signif-
icantly associated. For baseline BCG-naïve humans, Indonesian cynomolgus macaques
and Indian rhesus macaques best predicted the immune response. For baseline BCG-
vaccinated humans, Mauritian cynomolgus macaques best predicted the immune
response.
A key strength of this proof-of-concept study was the application of mathematical
modeling techniques to vaccine data that are rarely explored quantitatively. We used
established robust quantitative and statistical frameworks (compartmental mathemat-
ical models with nonlinear mixed-effects modeling [NLMEM] [29]) to explore the
complex biological dynamics, giving an early example of the utility of IS/ID modeling.
The biological data we used were standardized between species, with respect to time
points and laboratory techniques, which allowed a direct comparison of the immune
responses to BCG vaccination.
Although our model was a highly simpliﬁed version of the complexities of the
immune system (see the discussion in the supplemental material for the main assump-
tions and their impact [Table S14]), analysis 1 showed that the model described the
TABLE 1 Population mean parameter estimates for analyses 1 and 2 for macaques and humansa
Parameter or statistic
Macaques Humans
All (analysis 1) Covariates (analysis 2) All (analysis 1) Covariates (analysis 2)
Value RSE (%) Subpop. Value RSE (%) Value RSE (%) Subpop. Value RSE (%)
Parameter (unit)
Initial no. of TEM cells (TEM0) (cells) (E) 20.7 29 Chi 0.29 39* 59.9 17 BCG: Y 149 15
Maur 65.1 24
Indo 23.2 41* BCG: N 30.6 14
R: Ind 15.7 20
Gamma PDF curve multiplier (L) (scalar) (E) 1,170 13 Chi 617 43* 1,490 14 BCG: Y 3,240 14
Maur 1,460 28
Indo 1,100 45* BCG: N 747 14
R: Ind 1,250 14
Gamma PDF curve shape parameter (k) (scalar) (E) 3.31 5 Chi 4.3 11 1.45 9 1.55 16
Maur 3.15 10
Indo 3 20
R: Ind 3.53 6
Gamma PDF curve scale parameter (h) (scalar) (E) 15 8 13.8 7 18.4 18 BCG: Y 21.7 24
BCG: N 15.2 34*
Initial no. of CM cells (CM0) (cells) (F) 0 0 0 0
TEM cell terminal mortality rate (TEM) (/day) (F) 0.1 0.1 0.083 0.083
Proportion of TEM cells that die (p) (proportion) (F) 0.925 0.925 0.925 0.925
Within-population variation (WPV) (%)
Initial TEM cell population (TEM0) 130 25 41 27 107 15 52 19
Gamma PDF curve multiplier (L) 96 13 90 13 95 10 61 12
Gamma PDF curve shape parameter (k) 24 24 23 24 25 28 32 33*
Gamma PDF curve scale parameter (h) 19 21 21 20 58 25 43 37*
Goodness-of-ﬁt statistics
2LL 7,209 7,183 2,738 2,653
BIC 7,253 7,251 2,779 2,706
aFor details on the parameter-covariate relationship, see the supplemental material. F, ﬁxed; E, estimate; TEM, transitional effector memory; CM, central memory; PDF,
probability density function; RSE, relative standard error; subpop., subpopulation; Chi, Chinese cynomolgus macaques; Maur, Mauritian cynomolgus macaques; Indo,
Indonesian cynomolgus macaques; R: Ind, Indian rhesus macaques; BCG: Y, human participants who were BCG vaccinated at baseline; BCG: N, human participants
who were BCG naive at baseline; 2LL, 2 log likelihood; BIC, Bayesian information criteria. RSEs of 30% are marked with asterisks.
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data well. The model was also a good description of the subpopulation data in analysis
2. However, when the model was calibrated to smaller subpopulation sizes (especially
for the Chinese and Indonesian cynomolgus macaques), the estimated model param-
eters were more uncertain than for the larger populations (see the relative standard
error [RSE] values in Table 1). Access to larger data sets on these populations would
increase the certainty of the parameter estimates. Additionally, in analysis 2, our aim
was to establish how population covariates affect the model parameters using a
stepwise addition method. However, as Whittingham et al. point out, there are inherent
drawbacks with such a method, despite its widespread use (30).
By modeling the recruitment rate of transitional effector memory cells by the function
, we were able to represent the nonlinear stimulation of the CD4 T cell response
following BCG vaccination, allowing comparison of the dynamics of the response
FIG 2 VPC plots showing the number of IFN- SFU per million PMBC, by time (days) for all macaques (A) and all humans (B).
The VPC plot assesses the appropriateness of the proposed mathematical model (Fig. 1) for describing the empirical data by
comparing the data simulated using the model, the population mean parameters, and associated variances (Table 1) to the
empirical data distribution (see the supplemental material for more details). Blue points show empirical data. Pink regions
represent the ranges of the medians of the simulated data for 500 simulations. Blue regions represent the ranges of the 90th
and 10th percentiles of the simulated population data. The green lines link the empirical percentiles (10th, 50th, and 90th).
Dark red regions show where the empirical data fall outside the ranges of the simulated percentiles. The lack of dark red
regions (aside from cases in which data are variable between time points in macaques) indicates that our proposed
mathematical model (Fig. 1) adequately represents the empirical data.
Predicting BCG IFN- Responses in Humans from Macaques Clinical and Vaccine Immunology
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between subpopulations. However, since the recruitment rate of transitional effector
memory cells was not based on biological data and was characterized by a theoretical
shape, it is difﬁcult to make direct biological interpretations of the parameters. To
incorporate a mechanistic stimulation curve in future work, data on the cells involved
in the stimulation response would be required.
The results in this analysis were consistent with previous work, in which we applied
descriptive statistics to the human data (28). In that study, men experienced a higher
baseline IFN- response (P  0.1) than women. A similar pattern can be seen in the
current work: the median initial number of transitional effector memory cells (TEM0) for
men is higher than that of women (Fig. S8 in the supplemental material). Additionally,
the model in analysis 2 is consistent with our previous ﬁndings (28) for humans, in
which immune responses were higher in magnitude and were sustained longer for
baseline BCG-vaccinated humans than for baseline BCG-naïve humans. Therefore, our
results suggest that BCG revaccination provides a higher and more sustained IFN-
response than primary vaccination in humans. Finally, our results suggest that there are
differences in BCG response between different colonies of macaques. This is consistent
with work by Langermans et al., who show that rhesus macaques experience a higher
IFN- response 13 weeks after BCG vaccination than cynomolgus macaques (22),
although the potential effect of the colony on IFN- response was not highlighted in
that work. Differences in responses across macaque colonies have also been found in
M. tuberculosis challenge studies: Sharpe et al. showed that the AUC12Week (area under
the concentration-time curve at 12 weeks) values for IFN--secreting CD4 T cells were
signiﬁcantly higher for Indian rhesus macaques than for Indonesian cynomolgus (21).
Although we do not consider M. tuberculosis challenge in our analysis, these differences
may be important to consider when one is selecting an NHP model for human
mycobacterial immune response.
Our results imply that responses in Indonesian cynomolgus macaques, followed by
those in Indian rhesus macaques, most closely resembled the response in primary-
vaccinated humans determined by enzyme-linked immunospot (ELISPOT) assays. How-
ever, we approach this conclusion with caution, since the sample sizes of the macaque
FIG 3 Total number of T cells secreting IFN- (the sum of the number of transitional effector memory
cells and resting central memory cells) over time. Each point represents the mean of the data at a
particular time point. Lines represent model predictions. Model predictions use the estimated subpop-
ulation model parameters from Table 1 for the four macaque colonies and the two human subpopula-
tions with different BCG statuses. (Note the differences in scale between macaques and humans.)
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colony subpopulations were variable. With these smaller sample sizes, model param-
eterization and validation are less reliable than for larger groups. More data on the
colonies with small sample sizes should be collected and remodeled to verify our
results. Nevertheless, the large sample size obtained for the Indian rhesus macaques
was collated over decades of experimentation. Conventional vaccine studies in ma-
caques are often limited to 6 to 9 animals per group due to space and cost. These
smaller macaque experiments are then used to inform clinical vaccine trials, making our
small sample sizes more representative of current vaccine development than the large
rhesus macaque data set.
It should be noted that in terms of BCG vaccination history, the baseline BCG-naive
human subpopulation is the most comparable to all of the macaque subpopulations.
FIG 4 Mean immune responses of the four macaque colonies and of human subpopulations that were
BCG vaccinated (BCG: Y) or BCG naïve (BCG: N) at baseline. Empirical data for human responses are
represented by black points (individual data) and red triangles (means). Lines show model predictions.
The tables show the results of assessments of the ability of the calibrated macaque colony mathematical
model parameters (Table 1, analysis 2) to describe the data for the human BCG: Y and BCG: N
subpopulations. Bayesian information criterion (BIC) values are listed in ranked order, from lowest to
highest. Asterisks indicate that all differences in BIC values are signiﬁcant (a BIC value difference of 6
is considered signiﬁcant [46]). cyn., cynomolgus.
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Mauritian cynomolgus macaques mounted the highest response to a primary BCG
vaccination, and therefore, their data most closely resemble those for revaccination in
humans. However, it is apparent from Fig. 4 that the BCG-vaccinated humans experi-
enced a considerably higher magnitude of responses than all of the macaque sub-
populations (which were BCG naïve at baseline). This suggests that the immune
response to an antigen encountered for the ﬁrst time is lower and slower than the
response induced to the same antigen on subsequent occasions (31). Our results
therefore suggest that a revaccinated macaque animal model may be most appropriate
for revaccinated humans. This should be considered in further IS/ID translational
analysis between macaques and humans.
In our analyses, we consider only a UK-based human population. In future evalua-
tions, an analysis similar to that presented here could be carried out on populations
from various geographical locations, since BCG responses have been shown to differ by
geographic location (32). Other population covariates, such as age, may also be
important (8). Additionally, the question of whether this analysis will be appropriate for
other candidate vaccines would beneﬁt from further scrutiny.
Figure 5 explores the dynamics of the constituent T cell populations and provides
insights into how and when memory may be developed—an important consideration
in vaccine regimen design, i.e., the timing of revaccination and differences between
subpopulations. However, we do not currently have data to support these dynamics, so
future work could be undertaken using ﬂow cytometry to characterize the relative
numbers of complex phenotypic cell types over time and thus to inform models that
can provide a better understanding of T-cell dynamics.
In this analysis, we used solely IFN- as a proxy for BCG vaccine immunogenicity (33)
and did not consider BCG efﬁcacy measures explicitly. We understand that in order to
develop a vaccine, both immunogenicity and efﬁcacy are vital considerations. There-
fore, in predicting which macaque model best represents the human vaccine response,
vaccine efﬁcacy cannot be ignored. However, to incorporate efﬁcacy would require
FIG 5 Mean IFN- response data (black points) and model predictions for the total number of T cells
secreting IFN- (black lines), the number of transitional effector memory (TEM) cells (green lines), and the
number of resting central memory (CM) cells (orange lines) over time. Model predictions use the
estimated subpopulation model parameters from Table 1 for the four macaque colonies and the two
human subpopulations with different BCG statuses. (Note the differences in scale between macaques
and humans.)
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more-complex models and data than those we present here. As more immunological
information or functional parameters become available, IS/ID modeling methods will
allow us to easily integrate new information, e.g., on cytokines, cells, or (for efﬁcacy
measures) bacterial counts. Thus, we will be able to make decisions on the best NHP
model to use based on a more complete vaccine performance framework.
Conclusion. This work suggests that the immune responses of different human
subpopulations may be best modeled by different macaque colonies, and it demon-
strates the potential utility of immunostimulation/immunodynamic modeling to accel-
erate the development of TB vaccines.
MATERIALS AND METHODS
Data. Data on the number of puriﬁed protein derivative (PPD)-stimulated CD4 T cells secreting
IFN- (in spot forming units [SFU] per 1 million peripheral blood mononuclear cells [PBMC]), measured
by an ex vivo IFN- ELISPOT assay, were available for 55 humans and 81 macaques. BCG vaccination was
given on day zero, and ELISPOT measurements were performed up to 140 days after vaccination. The
details of the human data set and laboratory techniques have been published previously (28). Brieﬂy,
healthy UK volunteers aged 18 to 55 years, either with no history of BCG vaccination or previously
immunized with BCG, were given 100 l of BCG, administered intradermally in the upper arm. Immune
responses to BCG were measured using an IFN- ELISPOT assay at weeks 1, 4, 8, and 24. For demo-
graphics and laboratory details, see the supplemental material (Table S1; Fig. S1). All macaque studies
were conducted in accordance with the Home Ofﬁce (UK) Code of Practice for the Housing and Care of
Animals Used in Scientiﬁc Procedures (1989) and the Guidelines on Primate Accommodation, Care and
Use of the National Committee for Reﬁnement, Reduction and Replacement (NC3Rs), issued in August
2006. All animal procedures were approved by the Public Health England, Porton Down Ethical Review
Committee, and were authorized under an appropriate UK Home Ofﬁce project license. Vaccination,
sample collection procedures, and immunological methods are described in full in references 19, 23, 34,
and 35). All macaques were demonstrated to be mycobacterially naïve prior to BCG vaccination and were
between the ages of 3 and 14 years. The human population covariates were baseline (before vaccination
at time zero) BCG vaccination status (either BCG vaccinated [BCG: Y] or BCG naïve [BCG: N] at baseline),
years since BCG vaccination (grouped as 1 to 9, 10 to 19, or 20 to 29 years, or “never”), gender, and
monocyte-to-lymphocyte cell count ratio (ML ratio). The macaque population covariate was the colony
of origin (Indian rhesus macaques; for cynomolgus macaques, Chinese, Mauritian, or Indonesian [see
Table S2 and Fig. S2 in the supplemental material]). Rhesus macaques and cynomolgus macaques of the
Indonesian and Mauritian genotypes were obtained from established UK breeding colonies. Chinese
cynomolgus macaques were imported from a Home Ofﬁce-approved breeding colony in China.
Mathematical IS/ID model. An ordinary differential-equation model was used to describe the IFN-
response dynamics of two CD4 T cell populations, transitional effector memory (36) and resting
“central” memory cells, which are short- and long-lived, respectively (37–39) (Fig. 1). Brieﬂy, cells were
recruited into the transitional effector memory compartment at rate . A proportion (p) of transitional
effector memory cells underwent apoptosis at rate TEM, and the remaining proportion (1  p)
transitioned to a central memory phenotype, where they stayed for the duration of the model run (170
days) (Fig. 1). Central memory cells are quiescent in the host until stimulated by an antigen (31); however,
we considered them here to contribute to IFN- production, since the ELISPOT assay uses PPD to
stimulate all potentially IFN--secreting CD4 T cells. To reﬂect this, the IFN- immune response
predicted by the mathematical model was the sum of the number of transitional effector memory and
central memory cell populations over time. We assumed that any nonzero responses at baseline were
existing memory responses that had immediately reverted to the transitional effector memory pheno-
type in the presence of an antigen. Therefore, the initial transitional effector memory population (TEM0)
was positive for those subjects. We assumed that the increases in the number of transitional effector
memory and central memory cells did not occur immediately after vaccination but gradually increased
over time due to immune processes such as vaccine antigen trafﬁcking and presentation (31, 40). This
increase then subsided, as T cell stimulation was assumed not to last indeﬁnitely (31, 40–43). The
recruitment of transitional effector memory cells over time was controlled in the model using the re-
cruitment rate , which was a peaked curve speciﬁed using a gamma probability density function (PDF)
distribution with parameters L, k, and h (Fig. 1).
Analyses. (i) Analysis 1. Calibration of the model to IFN- data and exploration of model
predictions for macaques and humans separately. In analysis 1, the model was calibrated to the
macaque and human data separately to quantify the dynamics of the IFN- response for each species.
To do this, three parameters (the components of function : L, k, and h [Fig. 1]) and TEM0, the initial
number of transitional effector memory cells, were estimated using the established method of nonlinear
mixed effects modeling (NLMEM) (29) using the software Monolix v. 4.3.3 (44). Brieﬂy, NLMEM uses
maximum likelihood methods to estimate the model parameters that best describe the population mean
response and the associated parameter variance which accounts for the within-population variation (for
more details see reference 45). Evaluation of the model’s ability to describe the data was conducted
primarily by simulation-based, visual predictive check (VPC) plots (see the supplemental material for
details); assessment of the precision of the estimated parameters using the relative standard error (RSE)
and a goodness of ﬁt measure (Bayesian Information Criteria [BIC]). A difference in BIC of 6 was
considered a signiﬁcant (P value  0.05) effect (46) and a parameter RSE of 30% was considered a
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well-estimated parameter. The proportion of transitional effector memory cells that die (p) was assumed
to be 0.925, as supported by literature (38) (Fig. 1; Table 1) and the parameter governing the mortality
rate of transitional effector memory cells, E, was ﬁxed after a scenario analysis was conducted (Table S3).
Further tests required to establish the NLMEM framework are outlined in Tables S4 to S6.
(ii) Analysis 2. Population covariate impact on within-population variation in model parameter
estimates. In analysis 2, we explored whether population covariates (i.e., subpopulations, such as
different colonies) could reduce the within-population variation of the estimated parameters from that
in analysis 1, and we thus established subpopulation models for macaques and humans separately. To
do this, covariate-parameter relationships were tested and selected based on a forward-addition strategy
and likelihood ratio test method (see the supplemental material for details). Once the appropriate
covariate-parameter relationship was found, the subpopulation model was calibrated to the data and the
subpopulation parameters estimated. We observed the change in the BIC values and within-population
variation of model parameters from analysis 1 to analysis 2 as a result of accounting for the population
covariates.
(iii) Analysis 3. Which macaque subpopulations best predicted immune responses in different
human subpopulations? To evaluate which macaque subpopulations best predicted the immune
responses in different human subpopulations, estimated parameters and parameter variances from the
macaque subpopulation model (analysis 2) were ﬁt to the human data (or human subpopulation data
[analysis 2]). The subpopulation of macaques that best described the human data was deﬁned as the
model with the lowest BIC.
(iv) Analysis 4. Predicted numbers of TEM and resting CM cells over time. The calibrated
mathematical model was then used to predict the number of transitional effector memory (36) and
resting central memory cells over time. These dynamics were not measured empirically.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/
CVI.00525-16.
SUPPLEMENTAL FILE 1, PDF ﬁle, 3.6 MB.
ACKNOWLEDGMENTS
We thank our colleagues at INSERM (J. Guedj and F. Mentre), Paris, France, who
provided training on NLMEM methods.
S.J.R. is supported by a LSHTM studentship funded by Aeras. G.M.K. is funded by the
National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in
Healthcare Associated Infection and Antimicrobial Resistance at Imperial College Lon-
don in partnership with Public Health England (PHE). The views expressed are those of
the authors and not necessarily those of the NHS, the NIHR, the Department of Health,
or Public Health England. R.G.W. is funded by the UK Medical Research Council (MRC)
and the UK Department for International Development (DFID) under the MRC/DFID
Concordat agreement, which is also part of the EDCTP2 program supported by the
European Union (MR/P002404/1), the Bill and Melinda Gates Foundation (TB Modeling and
Analysis Consortium: OPP1084276/OPP1135288, SA Modeling for Policy: OPP1110334,
CORTIS: OPP1137034, Vaccines: OPP1160830), and UNITAID (4214-LSHTM-Sept15; PO 8477-
0-600).
We declare no competing ﬁnancial interests.
REFERENCES
1. WHO. 2015. Global tuberculosis report 2015. World Health Organization,
Geneva, Switzerland.
2. Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, Fine PE, Rodrigues
LC, Smith PG, Lipman M, Whiting PF, Sterne JA. 2014. Protection by BCG
vaccine against tuberculosis: a systematic review of randomized
controlled trials. Clin Infect Dis 58:470–480. https://doi.org/10.1093/
cid/cit790.
3. Dye C. 2013. Making wider use of the world’s most widely used vaccine:
Bacille Calmette-Guerin revaccination reconsidered. J R Soc Interface
10:20130365. https://doi.org/10.1098/rsif.2013.0365.
4. Dye C, Glaziou P, Floyd K, Raviglione M. 2013. Prospects for tuberculosis
elimination. Annu Rev Public Health 34:271–286. https://doi.org/10.1146/
annurev-publhealth-031912-114431.
5. Acosta A, Norazmi MN, Hernandez-Pando R, Alvarez N, Borrero R, Infante
JF, Sarmiento ME. 2011. The importance of animal models in tubercu-
losis vaccine development. Malays J Med Sci 18:5–12.
6. Tanner R, McShane H. 26 September 2016. Replacing, reducing and
reﬁning the use of animals in tuberculosis vaccine research. ALTEX
https://doi.org/10.14573/altex.1607281.
7. Flynn JL, Gideon HP, Mattila JT, Lin PL. 2015. Immunology studies in
non-human primate models of tuberculosis. Immunol Rev 264:60–73.
https://doi.org/10.1111/imr.12258.
8. McShane H, Williams A. 2014. A review of preclinical animal models
utilised for TB vaccine evaluation in the context of recent human efﬁcacy
data. Tuberculosis (Edinb) 94:105–110. https://doi.org/10.1016/j.tube
.2013.11.003.
9. Carlsson HE, Schapiro SJ, Farah I, Hau J. 2004. Use of primates in
research: a global overview. Am J Primatol 63:225–237. https://doi.org/
10.1002/ajp.20054.
10. Gormus BJ, Blanchard JL, Alvarez XH, Didier PJ. 2004. Evidence for a
rhesus monkey model of asymptomatic tuberculosis. J Med Primatol
33:134–145. https://doi.org/10.1111/j.1600-0684.2004.00062.x.
11. Capuano SV, III, Croix DA, Pawar S, Zinovik A, Myers A, Lin PL, Bissel S,
Fuhrman C, Klein E, Flynn JL. 2003. Experimental Mycobacterium tuber-
Rhodes et al. Clinical and Vaccine Immunology
March 2017 Volume 24 Issue 3 e00525-16 cvi.asm.org 10
 o
n
 January 8, 2018 by London School of Hygiene & Tropical M
edicine
http://cvi.asm
.org/
D
ow
nloaded from
 
culosis infection of cynomolgus macaques closely resembles the various
manifestations of human M. tuberculosis infection. Infect Immun 71:
5831–5844. https://doi.org/10.1128/IAI.71.10.5831-5844.2003.
12. Pena JC, Ho WZ. 2015. Monkey models of tuberculosis: lessons learned.
Infect Immun 83:852–862. https://doi.org/10.1128/IAI.02850-14.
13. Kaushal D, Mehra S, Didier PJ, Lackner AA. 2012. The non-human primate
model of tuberculosis. J Med Primatol 41:191–201. https://doi.org/
10.1111/j.1600-0684.2012.00536.x.
14. Scanga CA, Flynn JL. 2014. Modeling tuberculosis in nonhuman pri-
mates. Cold Spring Harb Perspect Med 4:a018564. https://doi.org/
10.1101/cshperspect.a018564.
15. Barclay WR, Anacker RL, Brehmer W, Leif W, Ribi E. 1970. Aerosol-induced
tuberculosis in subhuman primates and the course of the disease after
intravenous BCG vaccination. Infect Immun 2:574–582.
16. Janicki BW, Good RC, Minden P, Affronti LF, Hymes WF. 1973. Immune
responses in rhesus monkeys after bacillus Calmette-Guerin vaccination
and aerosol challenge with Mycobacterium tuberculosis. Am Rev Respir
Dis 107:359–366.
17. Reed SG, Coler RN, Dalemans W, Tan EV, De La Cruz EC, Basaraba RJ,
Orme IM, Skeiky YA, Alderson MR, Cowgill KD, Prieels JP, Abalos RM,
Dubois MC, Cohen J, Mettens P, Lobet Y. 2009. Deﬁned tuberculosis
vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus mon-
keys. Proc Natl Acad Sci U S A 106:2301–2306. https://doi.org/10.1073/
pnas.0712077106.
18. Kaushal D, Foreman TW, Gautam US, Alvarez X, Adekambi T, Rangel-
Moreno J, Golden NA, Johnson AM, Phillips BL, Ahsan MH, Russell-
Lodrigue KE, Doyle LA, Roy CJ, Didier PJ, Blanchard JL, Rengarajan J,
Lackner AA, Khader SA, Mehra S. 2015. Mucosal vaccination with atten-
uated Mycobacterium tuberculosis induces strong central memory re-
sponses and protects against tuberculosis. Nat Commun 6:8533. https://
doi.org/10.1038/ncomms9533.
19. White AD, Sarfas C, West K, Sibley LS, Wareham AS, Clark S, Dennis MJ,
Williams A, Marsh PD, Sharpe SA. 2015. Evaluation of the immunoge-
nicity of Mycobacterium bovis BCG delivered by aerosol to the lungs of
macaques. Clin Vaccine Immunol 22:992–1003. https://doi.org/10.1128/
CVI.00289-15.
20. Sharpe SA, Eschelbach E, Basaraba RJ, Gleeson F, Hall GA, McIntyre A,
Williams A, Kraft SL, Clark S, Gooch K, Hatch G, Orme IM, Marsh PD,
Dennis MJ. 2009. Determination of lesion volume by MRI and stereology
in a macaque model of tuberculosis. Tuberculosis (Edinb) 89:405–416.
https://doi.org/10.1016/j.tube.2009.09.002.
21. Sharpe S, White A, Gleeson F, McIntyre A, Smyth D, Clark S, Sarfas C,
Laddy D, Rayner E, Hall G, Williams A, Dennis M. 2016. Ultra low dose
aerosol challenge with Mycobacterium tuberculosis leads to divergent
outcomes in rhesus and cynomolgus macaques. Tuberculosis (Edinb)
96:1–12. https://doi.org/10.1016/j.tube.2015.10.004.
22. Langermans JA, Andersen P, van Soolingen D, Vervenne RA, Frost PA,
van der Laan T, van Pinxteren LA, van den Hombergh J, Kroon S, Peekel
I, Florquin S, Thomas AW. 2001. Divergent effect of bacillus Calmette-
Guerin (BCG) vaccination on Mycobacterium tuberculosis infection in
highly related macaque species: implications for primate models in
tuberculosis vaccine research. Proc Natl Acad Sci U S A 98:11497–11502.
https://doi.org/10.1073/pnas.201404898.
23. Javed S, Marsay L, Wareham A, Lewandowski KS, Williams A, Dennis MJ,
Sharpe S, Vipond R, Silman N, Ball G, Kempsell KE. 2016. Temporal
expression of peripheral blood leukocyte biomarkers in a Macaca fas-
cicularis infection model of tuberculosis; comparison with human data-
sets and analysis with parametric/non-parametric tools for improved
diagnostic biomarker identiﬁcation. PLoS One 11:e0154320. https://
doi.org/10.1371/journal.pone.0154320.
24. The Collaboration for TB Vaccine Discovery (CVTD). 2014. BMGF TB
vaccine strategy. https://www.ctvd.co/Pages/Strategy.aspx. Accessed
January 2017.
25. Knibbe CA, Zuideveld KP, Aarts LP, Kuks PF, Danhof M. 2005. Allometric
relationships between the pharmacokinetics of propofol in rats, children
and adults. Br J Clin Pharmacol 59:705–711. https://doi.org/10.1111/
j.1365-2125.2005.02239.x.
26. Dubois VF, de Witte WE, Visser SA, Danhof M, Della Pasqua O, Cardio-
vascular Safety Project Team, TI Pharma PKPD Platform. 2016. Assess-
ment of interspecies differences in drug-induced QTc interval prolonga-
tion in cynomolgus monkeys, dogs and humans. Pharm Res 33:40–51.
https://doi.org/10.1007/s11095-015-1760-9.
27. Mould DR, Upton RN. 2012. Basic concepts in population modeling,
simulation, and model-based drug development. CPT Pharmacometrics
Syst Pharmacol 1:e6. https://doi.org/10.1038/psp.2012.4.
28. Rhodes SJ, Knight GM, Fielding K, Scriba TJ, Pathan AA, McShane H,
Fletcher H, White RG. 2016. Individual-level factors associated with
variation in mycobacterial-speciﬁc immune response: gender and pre-
vious BCG vaccination status. Tuberculosis (Edinb) 96:37–43. https://
doi.org/10.1016/j.tube.2015.10.002.
29. Lavielle M. 2015. Mixed effects models for the population approach:
models, tasks, methods and tools. CRC Press, Boca Raton, FL.
30. Whittingham MJ, Stephens PA, Bradbury RB, Freckleton RP. 2006. Why
do we still use stepwise modelling in ecology and behaviour? J Anim
Ecol 75:1182–1189. https://doi.org/10.1111/j.1365-2656.2006.01141.x.
31. Abbas A, Lichtman A, Pillai S. 2015. Cellular and molecular immunology,
8th ed. Elsevier Saunders, Philadelphia, PA.
32. Weir RE, Black GF, Nazareth B, Floyd S, Stenson S, Stanley C, Branson K,
Sichali L, Chaguluka SD, Donovan L, Crampin AC, Fine PE, Dockrell HM.
2006. The inﬂuence of previous exposure to environmental mycobacte-
ria on the interferon-gamma response to bacille Calmette-Guerin vacci-
nation in southern England and northern Malawi. Clin Exp Immunol
146:390–399. https://doi.org/10.1111/j.1365-2249.2006.03222.x.
33. Fletcher HA. 2007. Correlates of immune protection from tuberculosis.
Curr Mol Med 7:319–325. https://doi.org/10.2174/156652407780598520.
34. White AD, Sibley L, Dennis MJ, Gooch K, Betts G, Edwards N, Reyes-
Sandoval A, Carroll MW, Williams A, Marsh PD, McShane H, Sharpe SA.
2013. Evaluation of the safety and immunogenicity of a candidate
tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of
macaques. Clin Vaccine Immunol 20:663–672. https://doi.org/10.1128/
CVI.00690-12.
35. Sharpe SA, McShane H, Dennis MJ, Basaraba RJ, Gleeson F, Hall G,
McIntyre A, Gooch K, Clark S, Beveridge NE, Nuth E, White A, Marriott A,
Dowall S, Hill AV, Williams A, Marsh PD. 2010. Establishment of an
aerosol challenge model of tuberculosis in rhesus macaques and an
evaluation of endpoints for vaccine testing. Clin Vaccine Immunol 17:
1170–1182. https://doi.org/10.1128/CVI.00079-10.
36. Seder RA, Darrah PA, Roederer M. 2008. T-cell quality in memory and
protection: implications for vaccine design. Nat Rev Immunol 8:247–258.
https://doi.org/10.1038/nri2274.
37. Pepper M, Jenkins MK. 2011. Origins of CD4() effector and central memory
T cells. Nat Immunol 12:467–471. https://doi.org/10.1038/nrm3166.
38. Kaech SM, Wherry EJ, Ahmed R. 2002. Effector and memory T-cell
differentiation: implications for vaccine development. Nat Rev Immunol
2:251–262. https://doi.org/10.1038/nri778.
39. McKinstry KK, Strutt TM, Swain SL. 2010. The potential of CD4 T-cell
memory. Immunology 130:1–9. https://doi.org/10.1111/j.1365-2567.2010
.03259.x.
40. Urdahl KB, Shaﬁani S, Ernst JD. 2011. Initiation and regulation of T-cell
responses in tuberculosis. Mucosal Immunol 4:288–293. https://doi.org/
10.1038/mi.2011.10.
41. Chackerian AA, Alt JM, Perera TV, Dascher CC, Behar SM. 2002. Dissem-
ination of Mycobacterium tuberculosis is inﬂuenced by host factors and
precedes the initiation of T-cell immunity. Infect Immun 70:4501–4509.
https://doi.org/10.1128/IAI.70.8.4501-4509.2002.
42. Cooper AM. 2009. Cell-mediated immune responses in tuberculosis.
Annu Rev Immunol 27:393– 422. https://doi.org/10.1146/annurev
.immunol.021908.132703.
43. De Rosa SC. 2004. Multicolor immunophenotyping: human mature im-
mune system. Methods Cell Biol 75:577–594. https://doi.org/10.1016/
S0091-679X(04)75024-4.
44. Lixoft. 2014. Monolix: user guide, version 4.3.3. Lixoft, Antony, France.
http://lixoft.com/ressources/legacy-documentation/.
45. Lavielle M, Mentre F. 2007. Estimation of population pharmacokinetic
parameters of saquinavir in HIV patients with the MONOLIX software. J
Pharmacokinet Pharmacodyn 34:229–249. https://doi.org/10.1007/
s10928-006-9043-z.
46. Raftery A. 1995. Bayesian model selection in social research. Sociolog
Methodol 25:111–163. https://doi.org/10.2307/271063.
Predicting BCG IFN- Responses in Humans from Macaques Clinical and Vaccine Immunology
March 2017 Volume 24 Issue 3 e00525-16 cvi.asm.org 11
 o
n
 January 8, 2018 by London School of Hygiene & Tropical M
edicine
http://cvi.asm
.org/
D
ow
nloaded from
 
